TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01434940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam
Description: . The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam
Description: . The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam
Description: . The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
Study: NCT04451798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella CP microaxial pump
Description: ramp test
Study: NCT03923868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
Study: NCT02177162

Intervention type: OTHER
Group type: OTHER
Intervention: Education to physiotherapists
Study: NCT03981510

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D-Transit
Description: 3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
Study: NCT00183248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor bone marrow stem cell infusion
Description: 2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplant
Description: Occurs at study entry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: Occurs at study entry
Study: NCT03790189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subchondral and intra-articular injection of BMC
Description: Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
Study: NCT04077502

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation
Study: NCT02012166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
Study: NCT03369808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5μg H7N9 Vaccine
Description: The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Solution
Description: 0.5ml phosphate buffer solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum Hydroxide Adjuvant
Description: 0.5ml aluminum hydroxide adjuvant
Study: NCT01589978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 antagonist
Description: Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided.~* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)
Study: NCT03369808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15μg H7N9 Vaccine
Description: The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30μg H7N9 Vaccine
Description: The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
Study: NCT01500889

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I: Conventional Lateral internal sphincterotomy:
Description: LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
Study: NCT01229566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKR-963
Description: 3600mg/day in capsules of AKR-963, Placebo, or Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AKR-963
Description: 3600mg/day in capsules of AKR-963, Placebo, or Active Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AKR-963
Description: 3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
Study: NCT01690273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobility exercise
Description: 30 minutes, twice a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobility and elastic resistance exercise
Description: 30 minutes, twice a week each exercises group. (total 1 hour)
Study: NCT03009292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: once daily continuous dosing
Study: NCT01500889

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GroupII: V-Y advancement flap
Description: GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GroupIII: Tailored LIS with V-Y advancement flap
Description: Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
Study: NCT04470726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001
Description: Intradermal/intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001
Description: Intradermal/intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001
Description: Intradermal/intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001
Description: Intradermal/intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001 suspension
Description: AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001 suspension
Description: AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001 suspension
Description: AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001 suspension
Description: AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection
Study: NCT00443456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
Study: NCT01192074

Intervention type: DEVICE
Intervention: Ultrasound
Description: Preprocedure ultrasound examination of the spine
Study: NCT01480648

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 144807 Placebo
Description: Placebo that represents BI drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807
Description: single dose (low to high dose)
Study: NCT02272478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A Mylotarg plus DA Versus CPX-351
Description: Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm B Vosaroxin and Decitabine
Description: If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm D Small molecule or Not
Description: The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm D Small molecule or Not
Description: The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm C DA V FLAG-Ida V DAC
Description: If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm E CPX-351 (200 V 300)
Description: If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
Study: NCT00950521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercerebral implantation of Autulogous Stem Cells
Description: 2-8 millions Stem cell per patients plus convention therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: convention therapy
Description: antiplatelet
Study: NCT03557385

Intervention type: DRUG
Group type: OTHER
Intervention: Iopamidol
Description: aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~* Rate of 4 mL/sec, volume of 10 cc (left coronary system)~* Rate of 3 mL/sec, volume of 6 cc (right coronary system).
Study: NCT02272478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm F DA V IDAC
Description: Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
Study: NCT03557385

Intervention type: DRUG
Group type: OTHER
Intervention: adenosine
Description: FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
Study: NCT02298231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Balance Intervention
Description: Standard balance therapy as performed by a physical therapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mystic Isle Balance Intervention
Description: Balance therapy using virtual reality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mystic Isle Balance Intervention with Dual Task
Description: Balance therapy using virtual reality and performing cognitive tasks
Study: NCT04153136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 49-51Mg Oral Tablet
Description: By mouth twice daily
Study: NCT01776411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Study: NCT02152800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir hydrocholoride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir hydrocholoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir hydrocholoride
Study: NCT04153136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet By mouth twice daily
Study: NCT02157610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help Materials
Description: Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
Study: NCT02677064

Intervention type: OTHER
Intervention: assessments
Description: All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.

Intervention type: OTHER
Intervention: assessments
Description: All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
Study: NCT03557385

Intervention type: DEVICE
Group type: OTHER
Intervention: Navvus® Catheter
Description: the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing

Intervention type: DEVICE
Group type: OTHER
Intervention: CVi® Contrast Delivery System
Description: The CVi® Contrast Delivery System will be used to deliver the contrast medium
Study: NCT02677064

Intervention type: OTHER
Intervention: assessments
Description: All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
Study: NCT04392752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dieting intervention
Description: This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.
Study: NCT02157610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke \>10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke \<10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke \>10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke \<10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDCap
Description: REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDCap
Description: REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva Test
Description: Saliva test performed at 3, 6, 12, and 18 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva Test
Description: Saliva test performed at 3, 6, 12, and 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling Sessions
Description: 6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
Study: NCT01186757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03715455
Description: PF-03715455 1.6 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03715455
Description: PF-03715455 4mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03715455
Description: PF-03715455 10 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03974061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
Study: NCT04290585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive text message reminders